CTI BioPharma announces FDA accelerated approval of Vonjo (pacritinib) for the treatment of adult patients with myelofibrosis and thrombocytopenia

CTI BioPharma

28 February 2022 - New drug application approved under priority review.

CTI BioPharma today announced the U.S. FDA has approved Vonjo (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

Read CTI BioPharma press release

Michael Wonder

Posted by:

Michael Wonder